Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

ClinicalTrials.gov ID: NCT00134238

Public ClinicalTrials.gov record NCT00134238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia

Study identification

NCT ID
NCT00134238
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
755 participants

Conditions and interventions

Interventions

  • torcetrapib/atorvastatin Drug
  • atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2003
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Feb 16, 2012

2003 – 2006

United States locations

U.S. sites
40
U.S. states
16
U.S. cities
40
Facility City State ZIP Site status
Pfizer Investigational Site Gilbert Arizona
Pfizer Investigational Site Phoenix Arizona
Pfizer Investigational Site Scottsdale Arizona
Pfizer Investigational Site Alhambra California
Pfizer Investigational Site Encinitas California
Pfizer Investigational Site La Jolla California
Pfizer Investigational Site Los Angeles California
Pfizer Investigational Site San Diego California
Pfizer Investigational Site Hartford Connecticut
Pfizer Investigational Site Melbourne Florida
Pfizer Investigational Site Palm Bay Florida
Pfizer Investigational Site Sebastian Florida
Pfizer Investigational Site Stuart Florida
Pfizer Investigational Site Vero Beach Florida
Pfizer Investigational Site Overland Park Kansas
Pfizer Investigational Site Boston Massachusetts
Pfizer Investigational Site Cambridge Massachusetts
Pfizer Investigational Site Edina Minnesota
Pfizer Investigational Site Minneapolis Minnesota
Pfizer Investigational Site Kansas City Missouri
Pfizer Investigational Site Concord New Hampshire
Pfizer Investigational Site Bronxville New York
Pfizer Investigational Site Buffalo New York
Pfizer Investigational Site Mount Vernon New York
Pfizer Investigational Site New York New York
Pfizer Investigational Site Williamsville New York
Pfizer Investigational Site Durham North Carolina
Pfizer Investigational Site Raleigh North Carolina
Pfizer Investigational Site Winston-Salem North Carolina
Pfizer Investigational Site Cincinnati Ohio
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Salt Lake City Utah
Pfizer Investigational Site Newport News Virginia
Pfizer Investigational Site Norfolk Virginia
Pfizer Investigational Site Richmond Virginia
Pfizer Investigational Site Bothell Washington
Pfizer Investigational Site Kirkland Washington
Pfizer Investigational Site Renton Washington
Pfizer Investigational Site Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00134238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00134238 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →